SCHEMBL2325282

SCHEMBL2325282

COP(=O)(CC(=O)C1(c2ccc(Cl)cc2)CC1)OC

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 3/20 0.47
HSD11B1 P28845 8/20 0.43
OPRM1 P35372 1/20 0.42
HDAC4 P56524 1/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2328536 0.94 HSD11B1 (0.46) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL6691484 0.85 AKR1C1 (0.42) HSD11B1OPRM1HDAC4HTTLMNA
SCHEMBL11623254 0.79 AKR1C1 (0.47) SMN1; SMN2ALDH1A1OPRM1HDAC4MEN1
SCHEMBL2325291 0.79 OPRM1 (0.45) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL15778834 0.77 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL13545175 0.76 HSD11B1 (0.51) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL1769917 0.76 HSD11B1 (0.51) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL2328542 0.74 MEN1 (0.45) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL4445340 0.74 HSD11B1 (0.53) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4
SCHEMBL5007609 0.74 HSD11B1 (0.53) SMN1; SMN2ALDH1A1HSD11B1OPRM1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 SMN1; SMN2 2843/4885ALDH1A1 91/4885HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.